K2 Principal Fund’s Oaktree Acquisition Corp III Life Sciences Warrant OACCW Stock Holding History

K2 Principal Fund’s Portfolio OACCW Stock Details OACCW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$37.9K	Buy	40,369 +1,311	+3%	+$1.1K	﹤0.01%	419
2026 Q1	$20.7K	Hold	39,058	–	–	﹤0.01%	445
2025 Q4	$27.7K	Hold	39,058	–	–	﹤0.01%	384
2025 Q3	$29.3K	Hold	39,058	–	–	﹤0.01%	318
2025 Q2	$34.4K	Hold	39,058	–	–	﹤0.01%	264
2025 Q1	$29.3K	Hold	39,058	–	–	﹤0.01%	292
2024 Q4	$34.4K	Buy	+39,058	New	+$25.5K	﹤0.01%	274

Other funds holding OACCW

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

DAM

Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

BGGS

Boussard & Gavaudan Gestion SAS Paris, France $1.99B AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

K2 Principal Fund's OACCW Position: Q2 2026 in Review

K2 Principal Fund increased its Oaktree Acquisition Corp III Life Sciences Warrant (OACCW) stake by 3.4% in Q2 2026, buying an estimated $1.1K and bringing the position to 40,369 shares worth $37.9K. The position accounts for ﹤0.01% of the portfolio, ranked #419.

K2 Principal Fund first reported a position in OACCW in Q4 2024 and has held it in 7 quarters since. 27 funds tracked by Wall St. Rank hold OACCW as of Q2 2026.

K2 Principal Fund held 40,369 shares of Oaktree Acquisition Corp III Life Sciences Warrant worth $37.9K as of Q2 2026.
K2 Principal Fund bought 1,311 Oaktree Acquisition Corp III Life Sciences Warrant shares in Q2 2026, an estimated $1.1K.
Oaktree Acquisition Corp III Life Sciences Warrant made up ﹤0.01% of K2 Principal Fund's portfolio in Q2 2026, its #419 holding.
K2 Principal Fund first reported a position in Oaktree Acquisition Corp III Life Sciences Warrant in Q4 2024 and has held it in 7 quarters since.
27 funds tracked by Wall St. Rank held Oaktree Acquisition Corp III Life Sciences Warrant as of Q2 2026.

Based on K2 Principal Fund's 13F filing for Q2 2026, filed 7 Aug 2026.